Refractory, primary Central Nervous System Neoplasm Recruiting Phase 2 Trials for Selpercatinib (DB15685)

Back to Refractory, primary Central Nervous System Neoplasm

Also known as: Refractory Primary Central Nervous System Neoplasm

IndicationStatusPhase
DBCOND0142769 (Refractory, primary Central Nervous System Neoplasm)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03155620Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)Screening